Trial Profile
A Phase I Study of LY2523355 in Patients With Advanced Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Aug 2018
Price :
$35
*
At a glance
- Drugs Litronesib (Primary) ; Pegfilgrastim
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 16 Jul 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov record.
- 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.